Page 131 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

References 129

[21] A.K. Abbas, A.H. Lichtman, S. Pillai, Cellular and Molecular Immunology E-Book,
Elsevier Health Sciences, (2014).
[22] L. Chiossone, P.Y. Dumas, M. Vienne, E. Vivier, Natural killer cells and other innate
lymphoid cells in cancer, Nat. Rev. Immunol. 18 (11) (2018) 671–688.
[23] A.S. Mirchandani, A.G. Besnard, E. Yip, C. Scott, C.C. Bain, V. Cerovic, et al. Type 2 innate
lymphoid cells drive CD4+ Th2 cell responses, J. Immunol. 192 (5) (2014) 2442–2448.
[24] I. Saranchova, J. Han, R. Zaman, H. Arora, H. Huang, F. Fenninger, et al. Type 2 innate
lymphocytes actuate immunity against tumours and limit cancer metastasis, Sci. Rep. 8
(1) (2018) 2924.
[25] R. Herberman, Natural cell-mediated immunity against tumors, Elsevier, (2012).
[26] E. Tomasello, M. Blery, E. Vely, E. Vivier, Signaling pathways engaged by NK cell recep-
tors: double concerto for activating receptors, inhibitory receptors and NK cells, Paper
presented at the seminars in immunology, (2000).
[27] H. Jiang, W. Zhang, P. Shang, H. Zhang, W. Fu, F. Ye, et al. Transfection of chimeric anti-
CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells,
Mol. Oncol. 8 (2) (2014) 297–310.
[28] N. Tarek, D.A. Lee, Natural killer cells for osteosarcoma, Current advances in osteosar-
coma, Springer, 2014, pp. 341–353.
[29] Z. Wang, Z. Wang, B. Li, S. Wang, T. Chen, Z. Ye, Innate immune cells: a potential and
promising cell population for treating osteosarcoma, Front. Immunol. 10 (2019) 1114.
[30] Y. Li, D.L. Hermanson, B.S. Moriarity, D.S. Kaufman, Human iPSC-derived natural
killer cells engineered with chimeric antigen receptors enhance anti-tumor activity, Cell
Stem Cell 23 (2) (2018) 181–192.
[31] X. Tang, L. Yang, Z. Li, A.P. Nalin, H. Dai, T. Xu, et al. First-in-man clinical trial of CAR
NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refrac-
tory acute myeloid leukemia, Am. J. Cancer Res. 8 (6) (2018) 1083.
[32] Y. Yang, O. Lim, T.M. Kim, Y.O. Ahn, H. Choi, H. Chung, et al. Phase I study of random
healthy donor–derived allogeneic natural killer cell therapy in patients with malignant
lymphoma or advanced solid tumors, Cancer Immunol. Res. 4 (3) (2016) 215–224.
[33] Y.B. Xie, J.Y. Zhang, M. DU, F.P. Meng, J.L. Fu, L.M. Liu, et al. Efficacy and peripheral
immunity analysis of allogeneic natural killer cells therapy in patients with hepatocellular
carcinoma, Beijing Da Xue Xue Bao Yi Xue Ban (Journal of Peking University. Health
Sciences) 51 (3) (2019) 591–595.
[34] L. Zhu, X.J. Li, S. Kalimuthu, P. Gangadaran, H.W. Lee, J.M. Oh, et al. Natural killer
cell (NK-92MI)-based therapy for pulmonary metastasis of anaplastic thyroid cancer in a
nude mouse model, Front. Immunol. 8 (2017) 816.
[35] T. Reya, H. Clevers, Wnt signalling in stem cells and cancer, Nature 434 (7035) (2005)
843.
[36] C.L. Zhang, T. Huang, B.L. Wu, W.X. He, D. Liu, Stem cells in cancer therapy: opportu-
nities and challenges, Oncotarget 8 (43) (2017) 75756.
[37] A. Borah, S. Raveendran, A. Rochani, T. Maekawa, D.S. Kumar, Targeting self-renewal
pathways in cancer stem cells: clinical implications for cancer therapy, Oncogenesis 4
(11) (2015) e177.
[38] H. Zhu, Y.S. Lai, Y. Li, R.H. Blum, D.S. Kaufman, Concise review: human pluripotent stem
cells to produce cell-based cancer immunotherapy, Stem Cells 36 (2) (2018) 134–145.
[39] S.S. Khan, M.A. Solomon, J.P. McCoy Jr., Detection of circulating endothelial cells and
endothelial progenitor cells by flow cytometry, Cytometry B Clin. Cytom. 64 (1) (2005)
1–8.